Caprock Group’s Intellia Therapeutics NTLA Stock Holding History

Caprock Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$233K	Buy	+13,786	New	+$193K	﹤0.01%	1117
2026 Q1	–	Sell	-10,159	Closed	-$91.3K	–	1235
2025 Q4	$91.3K	Sell	10,159 -523	-5%	-$7.2K	﹤0.01%	1160
2025 Q3	$121K	Buy	+10,682	New	+$132K	﹤0.01%	1091
2025 Q1	$71.6K	Buy	+10,068	New	+$102K	﹤0.01%	1046
2021 Q4	–	Sell	-1,514	Closed	-$203K	–	608
2021 Q3	$203K	Hold	1,514	–	–	0.02%	501
2021 Q2	$245K	Buy	+1,514	New	+$118K	0.02%	438

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Caprock Group's NTLA Position: Q2 2026 in Review

Caprock Group opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 13,786 shares worth $233K. The stake represents ﹤0.01% of the portfolio and ranks #1117 among its holdings. This is a return to the name: Caprock Group previously reported a position in NTLA as recently as Q4 2025.

Caprock Group first reported a position in NTLA in Q2 2021 and has held it in 6 quarters since. The position peaked at $245K in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Caprock Group held 13,786 shares of Intellia Therapeutics worth $233K as of Q2 2026.
Intellia Therapeutics was a new Caprock Group position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Caprock Group's portfolio in Q2 2026, its #1117 holding.
Caprock Group first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 6 quarters since.
Caprock Group's Intellia Therapeutics position peaked at $245K in Q2 2021.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.